BPMCBMPC 3% above buy level of double bottom pattern. MACD crossed above the signal line. Blueprint Medicines reported -11% earnings growth in the latest quarterly report. Revenue increased 63%.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.